• Policy
• Evrysdi also subject to prior authorization for reimb
• by Lee, Tak-Sun Jul 20, 2023 05:35am

• Policy
• The more applications for pre-screening drugs, the higher
• by Lee, Tak-Sun Jul 20, 2023 05:34am

• Company
• MET-targeting Tepmetko lands in general hospitals in KOR
• by Eo, Yun-Ho Jul 20, 2023 05:34am

• Company
• AZ and SK's Sidapvia is approved, first collab in 10 yrs
• by Jung, Sae-Im Jul 20, 2023 05:34am

• Policy
• MFDS organizes a Clinical Trial Consultative Body
• by Lee, Tak-Sun Jul 19, 2023 05:20am

• Policy
• 22 items that exploded in use during COVID-19,
• by Lee, Tak-Sun Jul 19, 2023 05:20am

• Policy
• No need to fear for the lack of Sabril after recall
• by Lee, Hye-Kyung Jul 19, 2023 05:20am

• Opinion
• [Reporter's view]Time to think about price by indication
• by Eo, Yun-Ho Jul 19, 2023 05:20am

• Company
• Power of K-combos...Rosuzet leads outpatient Rx drug market
• by Chon, Seung-Hyun Jul 19, 2023 05:20am

• Company
• Will GC Pharma enter the US blood product market in 2013?
• by Chon, Seung-Hyun Jul 19, 2023 12:28am